Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review.

Objective: To evaluate the available evidence comparing the use of the bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) regimen for 6 months with that of standard-of-care regimens for patients with multidrug-resistant or rifampin-resistant tuberculosis (MDR/RR-TB).

Methods: This was a systematic review of clinical trials comparing the use of the BPaLM regimen with the standard of care in patients with MDR/RR-TB. The main outcome measure was an unfavorable endpoint (a composite of death, treatment failure, treatment discontinuation, loss to follow-up, and recurrence), and secondary outcome measures included adverse events and serious adverse events.

Vascular outflow reconstruction in right lobe living donor liver transplantation with and without middle hepatic vein.

Although living donor liver transplantation has evolved, small-for-size syndrome remains a feared complication. Achieving optimal outflow for the graft with limited donor risk is possible with an experienced team and different techniques. Here we describe the technical aspects of living donor liver transplantation using a right lobe graft, including the different types of grafts, venous reconstructions and the importance of preoperative workup.

Per- and polyfluoroalkylated substances (PFAS) in the feathers and excreta of Gentoo penguins (Pygoscelis papua) from the Antarctic Peninsula.

Per- and polyfluoroalkyl substances (PFAS) exhibit widespread global distribution, extending to remote regions including Antarctica. Despite potential adverse effects on seabirds, PFAS exposure among Antarctic penguins remains poorly studied. We investigated the occurrence of 29 PFAS compounds in feathers and excreta of Gentoo penguins (Pygoscelis papua) from Fildes Bay, Antarctica.

LIVING DONOR LIVER TRANSPLANT FOR INTRAHEPATIC CHOLANGIOCARCINOMA. AN INITIAL BRAZILIAN EXPERIENCE.

Background: Intrahepatic cholangiocarcinoma (iCCA) was considered a contraindication for liver transplantation. However, recent studies have shown that highly selected cases of patients with a good response to neoadjuvant therapy may achieve acceptable survival rates when following liver transplantation.

Aims: To present two cases of patients with iCCA, without extrahepatic disease, who underwent living donor liver transplantation after receiving neoadjuvant chemotherapy.